Hosted on MSN1d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Too Old to Operate6d
Navigating Challenges in HSCT Eligibility for Myelofibrosis
Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...
Daily1d
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Medpage Today on MSN11d
Asymptomatic or Minimally Symptomatic Myelofibrosis
About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...
Too Old to Operate16d
Fedratinib as a Second-Line Treatment for Myelofibrosis After Ruxolitinib Intolerance
The following is a summary of “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open label, randomized, ...
Pharmabiz1d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Medscape9d
What Does the Future Look Like for Myelofibrosis?
What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...
Targeted Oncology10d
Phase 1 Study of Type II JAK2 Inhibitor in Myelofibrosis Enrolls First Patient
The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...
Karyopharm changes endpoint in Phase 3 trial of selinexor in myelofibrosis
Karyopharm (KPTI) announced that, following feedback from the FDA, the company will be replacing Total Symptom Score Improvement of greater ...
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...